Antipsychotic drugs: recent developments and novel agents

Bibliography

• MILLER DD: Schizophrenia: its etiology and impact.Pharmacotherapy (1996) 16(1 Pt2):2S–5S.
   Google Scholar
• DENIKER P: The Neuroleptics: a historical survey. Acta Psychiafr. Scand. (1990) 82 (Suppl. 358):83–87. A concise overview of the area.
   Google Scholar
• LIEBERMAN JA: Understanding the mechanism o f action of atypical antipsychotic drugs. Br. J Psychiatry (1993) 163\(Suppl. 22):7–18.
   Google Scholar
• TARSY D: Neuroleptic-induced extrapyramidal reac-tions: classification, description, and diagnosis. Clin. Neuropharmacol (1983) 6\(Suppl. 1):S9–S26.
   Google Scholar
• An expanding range of atypical antipsychotic agents to choose from. Drug Ther. Persp. (1996) 8(3):1–5.
   Google Scholar
• UMBRICHT D, KANE JM: Medical complications of new antipsychotic drugs. Schizophrenia Bull (1996) 22(3):475–483. Presents an excellent discussion of all associated liabilities with current therapeutic agents.
   Google Scholar
• OWENS DGC: Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs (1996) 51 (6):895–930.
   Google Scholar
• ROTH BL, CRAIGO SC, CHOUDARY MS et al: Binding of typical and atypical antipsychotic agents to 5-11T6 and 5-11T7 receptors. J. Pharmacol. Exp. Ther. (1994) 268(3)1403–1410.
   Google Scholar
• LEYSEN JE, JANSSEN PMF, MEGENS AAHP, SCHOTTE A:Risperidone: a novel antipsychotic with balanced se ro-tonin-dopamine antagonism, receptor occupancy pro-file, and pharmacological activity. J. Clin. Psychiatry (1994) 55(5):5–12.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM, TRAN PV, SANGER T: Olanzapine: an exciting atypical antipsychotic - the clinical experience. Eur. Neuropsychopharmacol (1995) 5 (3):Abstract SAT–5–5.
   Google Scholar
• GOLDSTEIN JM, ARVANITIS LA: ICI 204,636 (Sero- quel(TM)): dibenzothiazepine atypical antipsychotic. A review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev. (1995) 1(1):50–73. Zeneca has recently received approval for use of the generic name quetiapine for this compound and Seroquel will be employed as its trade name.
   Google Scholar
• SEEGER, TF, SEYMOUR PA, SCHMIDT AW et al.: Ziprasi-done (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Pharmacol. Exp. Ther. (1995) 275(0:101–113.
   PubMedGoogle Scholar
• MCDONNELL ME, REITZ AB: Recent advances in antipsy-chotic research. Exp. Opin. Ther. Patents (1994) 4 (10): 1221–1231.
   Google Scholar
• SCHWARTZ J-C, GIROS B, MARTRES M-P, SOKOLOFF P: The dopamine receptor family: mole cularbiology and phar-macology. Semin. NeuroscL (1992) 4:99–108.
   Google Scholar
• JABER M, ROBINSON SW, MISSALE C, CARON MG: Dopamine receptors and brain function. Neuropharma-col. (1996) 35(10:1503-1519. An excellent review of the current understanding of dopamine.
   Google Scholar
• HADLEY MS: D4 receptors and their antagonists. Med. Res. Rev. (1996) 16(6):507–526.
   PubMed Web of Science ®Google Scholar
• SEEMAN P, GUAN H-C, VAN TOL EIFIM: Dopamine D4 receptors elevated in schizophrenia. Nature (1993) 365:441–445.
   PubMed Web of Science ®Google Scholar
• ROBERTS DA, BALDERSON D, PICKERING-BROWN SM, DEAKIN JFW, OWEN F: The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. Schizophrenia Res (1996) 20:171–174.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP: The importance of dopamine D4 recep-tors in the action and development of antipsychotic agents. Drugs (1996) 51(0:7–11.
   PubMedGoogle Scholar
• FREEDMAN SB, PATEL S, MARWOOD R et aL: Expression and pharmacological characterization o f the human D3 dopamine receptor. J. Pharmacol. Exp. Ther. (1994) 268:417–426.
   PubMed Web of Science ®Google Scholar
• BARIK S, DE BEAUREPAIRE R: Evidence for a functional role of the dopamine D3 receptors in the cerebellum. Brain Res. (1996) 737:347–350.
   PubMed Web of Science ®Google Scholar
• JOYCE JN, SHANE A, LEXOW N et aL: Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacol. (1993) 8 (4) :315–336.
   PubMed Web of Science ®Google Scholar
• JOYCE JN: The dopamine hypothesis of schizophrenia: limbic interaction with serotonin and noradrenaline. Psychopharmacol. (1993) 112:S16–S34.
   Google Scholar
• REYNTJENS A, GELDERS YG, HOPPENBROUWERS M-L, BUSSCHE GV: Thymosthenic effects of ritanvrin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev. Res. (1986) 8:205–211.
   Web of Science ®Google Scholar
• SZYMANSKI S, LIEBERMAN J, POLLACK S et aL: The dopamine-serotonin relationship in clozapine re-sponse. Psychopharmacol (1993) 112:S85–S89.
   Web of Science ®Google Scholar
• LOWE III JA: Atypical antipsychotics based on the D215-11T2 ratio hypothesis. Curr. Med. Chem. (1994) 1:50-60. Excellent review of some investigational drugs.
   Google Scholar
• OHUOHA DC, HYDE TM, KLEINMAN JE: The role of serotonin in schizophrenia: an overview of the nomen-clature, distribution and alterations of serotonin recep - tors in the central nervous system. Psychopharmacol (1993) 112:S5-S15. Useful review of the serotonin area.
   Google Scholar
• WALKER JM, BOWEN WD, WALKER FO, MATSUMOTO RR, DE COSTA B, RICE KC: a Receptors: biology and function. Pharmacol Rev. (1990) 42:355–402.
   PubMed Web of Science ®Google Scholar
• Pharmaprojects. Hutton I (Ed.); PJB Publications Ltd., Surrey (1996) 17:a1693–1709.
   Google Scholar
• LOWE III JA, MCLEAN S: Tachykinin antagonists. Curr.Pharm. Design. (1995) 1:269–278.
   Google Scholar
• MAGGI CA, PATACCHINI R, ROVERO P, GIACHETTI A: Tachykinin receptors and tachykinin receptor antago-nists. Auto. Pharmacol (1993) 13:23–93.
   PubMedGoogle Scholar
• WELLER M, KORNHUBER J: N-Methyl-D-aspartate antago-nists, schizophrenia, and neuroleptic malignant syn-drome. Arch. Neurol (1992) 49:900–901.
   PubMedGoogle Scholar
• LIDSKY TI, BANERJEE SP: Contribution of glut amatergic dysfunction to schizophrenia. Drug News Persp. (1996) 9(8):453–459.
   Google Scholar
• FREEDMAN R, COON H, MYLES-WORSLEYM etaL: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. NatL Acad. Sci. USA (1997) 94:587–592.
   PubMed Web of Science ®Google Scholar